Cargando…
PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriers
BACKGROUND: In contrast to sporadic Alzheimer’s disease, autosomal dominant Alzheimer’s disease (ADAD) is associated with greater neuropathological evidence of cerebellar amyloid plaque (Aβ) deposition. In this study, we used positron emission tomography (PET) measurements of fibrillar Aβ burden to...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278433/ https://www.ncbi.nlm.nih.gov/pubmed/34252876 http://dx.doi.org/10.1016/j.nicl.2021.102749 |
_version_ | 1783722258681823232 |
---|---|
author | Ghisays, Valentina Lopera, Francisco Goradia, Dhruman D. Protas, Hillary D. Malek-Ahmadi, Michael H. Chen, Yinghua Devadas, Vivek Luo, Ji Lee, Wendy Baena, Ana Bocanegra, Yamile Guzmán-Vélez, Edmarie Pardilla-Delgado, Enmanuelle Vila-Castelar, Clara Fox-Fuller, Joshua T. Hu, Nan Clayton, David Thomas, Ronald G. Alvarez, Sergio Espinosa, Alejandro Acosta-Baena, Natalia Giraldo, Margarita M. Rios-Romenets, Silvia Langbaum, Jessica B. Chen, Kewei Su, Yi Tariot, Pierre N. Quiroz, Yakeel T. Reiman, Eric M. |
author_facet | Ghisays, Valentina Lopera, Francisco Goradia, Dhruman D. Protas, Hillary D. Malek-Ahmadi, Michael H. Chen, Yinghua Devadas, Vivek Luo, Ji Lee, Wendy Baena, Ana Bocanegra, Yamile Guzmán-Vélez, Edmarie Pardilla-Delgado, Enmanuelle Vila-Castelar, Clara Fox-Fuller, Joshua T. Hu, Nan Clayton, David Thomas, Ronald G. Alvarez, Sergio Espinosa, Alejandro Acosta-Baena, Natalia Giraldo, Margarita M. Rios-Romenets, Silvia Langbaum, Jessica B. Chen, Kewei Su, Yi Tariot, Pierre N. Quiroz, Yakeel T. Reiman, Eric M. |
author_sort | Ghisays, Valentina |
collection | PubMed |
description | BACKGROUND: In contrast to sporadic Alzheimer’s disease, autosomal dominant Alzheimer’s disease (ADAD) is associated with greater neuropathological evidence of cerebellar amyloid plaque (Aβ) deposition. In this study, we used positron emission tomography (PET) measurements of fibrillar Aβ burden to characterize the presence and age at onset of cerebellar Aβ deposition in cognitively unimpaired (CU) Presenilin-1 (PSEN1) E280A mutation carriers from the world’s largest extended family with ADAD. METHODS: (18)F florbetapir and (11)C Pittsburgh compound B (PiB) PET data from two independent studies – API ADAD Colombia Trial (NCT01998841) and Colombia-Boston (COLBOS) longitudinal biomarker study were included. The tracers were selected independently by the respective sponsors prior to the start of each study and used exclusively throughout. Template-based cerebellar Aβ-SUVR (standard-uptake value ratios) using a known-to-be-spared pons reference region (cerebellar SUVR_pons), to a) compare 28–56-year-old CU carriers and non-carriers; b) estimate the age at which cerebellar SUVR_pons began to differ significantly in carrier and non-carrier groups; and c) characterize in carriers associations with age, cortical SUVR_pons, delayed recall memory, and API ADAD composite score. RESULTS: Florbetapir and PiB cerebellar SUVR_pons were significantly higher in carriers than non-carriers (p < 0.0001). Cerebellar SUVR_pons began to distinguish carriers from non-carriers at age 34, 10 years before the carriers’ estimated age at mild cognitive impairment onset. Florbetapir and PiB cerebellar SUVR_pons in carriers were positively correlated with age (r = 0.44 & 0.69, p < 0.001), cortical SUVR_pons (r = 0.55 & 0.69, p < 0.001), and negatively correlated with delayed recall memory (r = −0.21 & −0.50, p < 0.05, unadjusted for cortical SUVR_pons) and API ADAD composite (r = −0.25, p < 0.01, unadjusted for cortical SUVR_pons in florbetapir API ADAD cohort). CONCLUSION: This PET study provides evidence of cerebellar Aβ plaque deposition in CU carriers starting about a decade before the clinical onset of ADAD. Additional studies are needed to clarify the impact of using a cerebellar versus pons reference region on the power to detect and track ADAD changes, even in preclinical stages of this disorder. |
format | Online Article Text |
id | pubmed-8278433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-82784332021-07-19 PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriers Ghisays, Valentina Lopera, Francisco Goradia, Dhruman D. Protas, Hillary D. Malek-Ahmadi, Michael H. Chen, Yinghua Devadas, Vivek Luo, Ji Lee, Wendy Baena, Ana Bocanegra, Yamile Guzmán-Vélez, Edmarie Pardilla-Delgado, Enmanuelle Vila-Castelar, Clara Fox-Fuller, Joshua T. Hu, Nan Clayton, David Thomas, Ronald G. Alvarez, Sergio Espinosa, Alejandro Acosta-Baena, Natalia Giraldo, Margarita M. Rios-Romenets, Silvia Langbaum, Jessica B. Chen, Kewei Su, Yi Tariot, Pierre N. Quiroz, Yakeel T. Reiman, Eric M. Neuroimage Clin Regular Article BACKGROUND: In contrast to sporadic Alzheimer’s disease, autosomal dominant Alzheimer’s disease (ADAD) is associated with greater neuropathological evidence of cerebellar amyloid plaque (Aβ) deposition. In this study, we used positron emission tomography (PET) measurements of fibrillar Aβ burden to characterize the presence and age at onset of cerebellar Aβ deposition in cognitively unimpaired (CU) Presenilin-1 (PSEN1) E280A mutation carriers from the world’s largest extended family with ADAD. METHODS: (18)F florbetapir and (11)C Pittsburgh compound B (PiB) PET data from two independent studies – API ADAD Colombia Trial (NCT01998841) and Colombia-Boston (COLBOS) longitudinal biomarker study were included. The tracers were selected independently by the respective sponsors prior to the start of each study and used exclusively throughout. Template-based cerebellar Aβ-SUVR (standard-uptake value ratios) using a known-to-be-spared pons reference region (cerebellar SUVR_pons), to a) compare 28–56-year-old CU carriers and non-carriers; b) estimate the age at which cerebellar SUVR_pons began to differ significantly in carrier and non-carrier groups; and c) characterize in carriers associations with age, cortical SUVR_pons, delayed recall memory, and API ADAD composite score. RESULTS: Florbetapir and PiB cerebellar SUVR_pons were significantly higher in carriers than non-carriers (p < 0.0001). Cerebellar SUVR_pons began to distinguish carriers from non-carriers at age 34, 10 years before the carriers’ estimated age at mild cognitive impairment onset. Florbetapir and PiB cerebellar SUVR_pons in carriers were positively correlated with age (r = 0.44 & 0.69, p < 0.001), cortical SUVR_pons (r = 0.55 & 0.69, p < 0.001), and negatively correlated with delayed recall memory (r = −0.21 & −0.50, p < 0.05, unadjusted for cortical SUVR_pons) and API ADAD composite (r = −0.25, p < 0.01, unadjusted for cortical SUVR_pons in florbetapir API ADAD cohort). CONCLUSION: This PET study provides evidence of cerebellar Aβ plaque deposition in CU carriers starting about a decade before the clinical onset of ADAD. Additional studies are needed to clarify the impact of using a cerebellar versus pons reference region on the power to detect and track ADAD changes, even in preclinical stages of this disorder. Elsevier 2021-07-04 /pmc/articles/PMC8278433/ /pubmed/34252876 http://dx.doi.org/10.1016/j.nicl.2021.102749 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Regular Article Ghisays, Valentina Lopera, Francisco Goradia, Dhruman D. Protas, Hillary D. Malek-Ahmadi, Michael H. Chen, Yinghua Devadas, Vivek Luo, Ji Lee, Wendy Baena, Ana Bocanegra, Yamile Guzmán-Vélez, Edmarie Pardilla-Delgado, Enmanuelle Vila-Castelar, Clara Fox-Fuller, Joshua T. Hu, Nan Clayton, David Thomas, Ronald G. Alvarez, Sergio Espinosa, Alejandro Acosta-Baena, Natalia Giraldo, Margarita M. Rios-Romenets, Silvia Langbaum, Jessica B. Chen, Kewei Su, Yi Tariot, Pierre N. Quiroz, Yakeel T. Reiman, Eric M. PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriers |
title | PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriers |
title_full | PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriers |
title_fullStr | PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriers |
title_full_unstemmed | PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriers |
title_short | PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriers |
title_sort | pet evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant alzheimer’s disease-causing presenilin-1 e280a mutation carriers |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278433/ https://www.ncbi.nlm.nih.gov/pubmed/34252876 http://dx.doi.org/10.1016/j.nicl.2021.102749 |
work_keys_str_mv | AT ghisaysvalentina petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT loperafrancisco petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT goradiadhrumand petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT protashillaryd petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT malekahmadimichaelh petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT chenyinghua petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT devadasvivek petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT luoji petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT leewendy petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT baenaana petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT bocanegrayamile petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT guzmanvelezedmarie petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT pardilladelgadoenmanuelle petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT vilacastelarclara petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT foxfullerjoshuat petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT hunan petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT claytondavid petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT thomasronaldg petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT alvarezsergio petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT espinosaalejandro petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT acostabaenanatalia petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT giraldomargaritam petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT riosromenetssilvia petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT langbaumjessicab petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT chenkewei petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT suyi petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT tariotpierren petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT quirozyakeelt petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers AT reimanericm petevidenceofpreclinicalcerebellaramyloidplaquedepositioninautosomaldominantalzheimersdiseasecausingpresenilin1e280amutationcarriers |